Abstract:The potential estrogenic activities of perfluoroalkyl substances (PFASs) are controversial. Here, we investigated the estrogenic/antiestrogenic activities of PFASs and explored the corresponding interaction mode of PFASs with the estrogen receptor (ER) by combining in vitro assays and in silico modeling. We found that three PFASs (perfluorobutanoic acid, perfluorobutane sulfonate, and perfluoropentanoic acid) exerted antiestrogenic effects by inhibiting luciferase activity, whereas perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) exerted estrogenic effects by inducing luciferase activity. When coexposed to 17β-estradiol (E2), all tested PFASs attenuated the E2-stimulated luciferase activity; unexpectedly, each PFAS could further attenuate the luciferase activity generated by the cotreatment with ICI 182,780 and E2, with a minimal effective concentration comparable to that found in human serum. PFHxS and PFOS significantly induced the gene expression of TFF1; additionally, all PFASs inhibited the E2-induced gene expression of TFF1 and EGR3. Furthermore, the results of the blind docking analyses suggested that the interaction with the coactivator-binding region on the ER surface should be included as a pathway through which PFASs exert estrogenic and antiestrogenic activities. Finally, we revealed the critical molecular property of the zero-order molecular connectivity index (MCI) (0χ) that affects the antiestrogenic activity of PFASs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.est.0c03468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.0c03468</a>.Structures of tested chemicals (Table S1); concentrations of PFASs in exposure solutions (Table S2); binding free energy components of E2 and PFOS in the ER–E2–PFOS complex (Table S3); compounds, parameters, and activity data (Table S4); RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) (part 1); in silico computational model (part 2); concentration–response luciferase activity of PFASs that gave a minor response in the MVLN assay (Figure S1); ERE-luciferase assay of PFASs in MVLN cells after cotreatment with E2 and ICI 182,780 (Figure S2); binding modes of 10 PFASs molecules in HIP molecular modeling (Figure S3); binding modes of 10 PFASs molecules in HIE molecular modeling (Figure S4); RMSD changes in MD simulations (Figure S5); and empirical distribution of R2* for the pEC50 model (Figure S6) (<a class="ext-link" href="/doi/suppl/10.1021/acs.est.0c03468/suppl_file/es0c03468_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Hazard and Risk Characterization and Grouping of 56 Structurally Diverse PFAS Using a Targeted Battery of Broad Coverage Assays in Six Human Cell Types

Hazard and Risk Characterization of 56 Structurally Diverse PFAS Using a Targeted Battery of Broad Coverage Assays Using Six Human Cell Types.

Risk-based prioritization of PFAS using phenotypic and transcriptomic data from human induced pluripotent stem cell-derived hepatocytes and cardiomyocytes

Characterizing PFAS hazards and risks: a human population-based in vitro cardiotoxicity assessment strategy

PFAS Exposure Pathways for Humans and Wildlife: A Synthesis of Current Knowledge and Key Gaps in Understanding

Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry

Per‐ and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research

In Vitro Hepatic Clearance Evaluations of Per- and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories

In vitro screening of understudied PFAS with a focus on lipid metabolism disruption

Assessing the human health risks of per- and polyfluoroalkyl substances: A need for greater focus on their interactions as mixtures

An integrated assessment of ecological and human health risks of per- and polyfluoroalkyl substances through toxicity prediction approaches

Comprehensive Exposure Studies of Per- and Polyfluoroalkyl Substances in the General Population: Target, Nontarget Screening, and Toxicity Prediction

Evaluation of the Estrogenic/Antiestrogenic Activities of Perfluoroalkyl Substances and Their Interactions with the Human Estrogen Receptor by Combining In Vitro Assays and In Silico Modeling

Screening Novel Per- and Polyfluoroalkyl Substances in Human Blood Based on Nontarget Analysis and Underestimated Potential Health Risks

Perfluoroalkyl substances and immunotoxicity: An in vitro structure-activity relationship study in THP-1-derived monocytes and macrophages

Comparative Developmental Toxicities of Zebrafish Towards Structurally Diverse Per- and Polyfluoroalkyl Substances.

A Roadmap to the Structure-Related Metabolism Pathways of Per- and Polyfluoroalkyl Substances in the Early Life Stages of Zebrafish ( Danio rerio )

Hepatic Transcriptome Comparative in Silico Analysis Reveals Similar Pathways and Targets Altered by Legacy and Alternative Per- and Polyfluoroalkyl Substances in Mice

Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment

Concentration-dependent toxicokinetics of novel PFOS alternatives and their chronic combined toxicity in adult zebrafish

Metabolic and phenotypic changes induced by PFAS exposure in two human hepatocyte cell models